News 14 January, 2025Xinnate receives Orphan Drug Designation from US FDA for TCP-25 17 December, 2024Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm 27 September, 2024Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa 5 September, 2024Xinnate presents TCP-25 data at international dermatology congress 7 May, 2024Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa 18 March, 2024Xinnate completes Phase 1a/b study with TCP-25 7 February, 2024Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa 18 March, 2023Xinnate appoints Anna-Karin Lindqvist as new COO 19 October, 2022Approved clinical trial application for BioC gel on complex wounds
